[Clinical effectiveness of short-term administration of monoclonal antibody cA2 against tumor necrosis factor alpha in Crohn disease].
Schreiber
S
S
Medizinische Klinik, Christian-Albrechts-Universität zu Kiel.
Koop
I
I
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy*; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D007262:Infusions, Intravenous; D051379:Mice; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha
Klinische Effektivität des Kurzzeiteinsatzes des monoklonalen Antikörpers cA2 gegen Tumor-Nekrose-Faktor alpha bei Morbus Crohn.